A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Morten Mau-Soerensen, Albiruni R. A. Razak, Anthony Frank Shields, Nashat Y. Gabrail, John F. Gerecitano, Sharon Shacham, Ulrik Niels Lassen, Tami Rashal, Jennifer Cooksey, Yosef Landesman, Gregory Pond, Amit M. Oza, Michael Kauffman, Lillian L. Siu, Philippe L. Bedard, Hemchandra Mahaseth, Mansoor Raza Mirza, Amit Mahipal
Institutions: Rigshospitalet, Princess Margaret Cancer Centre, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Gabrail Cancer Center, Memorial Sloan Kettering Cancer Center, Karyopharm Therapeutics (United States), Moffitt Cancer Center, Ozmosis Research (Canada), University Health Network
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4236486207